Workflow
药品集采反内卷,不再唯低价中选
21世纪经济报道·2025-09-20 14:11

Core Viewpoint - The new changes in the 11th batch of centralized drug procurement aim to enhance clinical drug supply, ensure quality, and prevent collusion among bidders, reflecting a shift towards a more practical and quality-focused procurement process [1][4][9]. Group 1: Key Changes in Procurement Rules - Change 1: The reporting method for medical institutions has been optimized, allowing them to report either by brand or by generic name, with 77% of reports specifying brands. This aims to improve the match between clinical demand and supply [1][4]. - Change 2: A new "revival for non-selected" rule has been introduced, allowing companies that did not initially qualify to enter the selection process if they meet specific criteria, including sufficient reporting from hospitals and a willingness to lower prices [2][4]. - Change 3: Three new qualification requirements for bidders have been established, including a minimum of two years of production experience and compliance with GMP standards, to ensure quality in the procurement process [5]. Group 2: Measures Against Collusion and Price Control - Change 4: A "first report leniency" mechanism has been introduced to encourage reporting of collusion, allowing companies that provide evidence of collusion to receive leniency in penalties [6]. - Change 5: The procurement process will no longer simply select the lowest bid. Instead, a new pricing anchor will be established to prevent extreme low bids from distorting the market, with adjustments made to ensure fairness [7][8]. - Change 6: Companies are required to justify any bids below the established anchor price, ensuring that pricing reflects actual costs and prevents unsustainable pricing practices [8].